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Abstract Lymph node staging is one of the most impor-
tant factors in determining the prognosis after resection of
pancreatic ductal adenocarcinoma. Despite ongoing efforts
to further refine lymph node staging, the debate on the extent
of lymphadenectomy during pancreaticoduodenectomy is
still open. The purpose of this review was to summarize the
evidence about performing standard lymphadenectomy
during curative resection of pancreatic cancer. All four
prospective randomized controlled trials published con-
cluded that extended lymphadenectomy does not contribute
to better oncologic outcome for patients with adenocarci-
noma of the pancreatic head. Indeed, one major drawback of
extended lymphadenectomy is the higher risk of persistent
postoperative diarrhea. No prospective randomized studies
could be found on the role of extended lymphadenectomy in
patients with adenocarcinoma of the corpus and tail. Based
on current evidence there is no indication that extended
lymphadenectomy should be performed routinely during
resection of pancreatic cancer.
Introduction
Despite continuous efforts to improve survival of patients
with pancreatic cancer, little progress has been achieved
over the past three decades, mainly because most patients
with pancreatic adenocarcinoma present at an advanced
stage. Although curative surgery is an option in fewer than
30 % of cases, it remains the only treatment that offers a
chance for long-term survival. The reported 5-year survival
rates after curative resection still range between 10 and
20 % [1].
Significant improvements in preoperative and postop-
erative tumor staging have considerably improved our
capability to estimate long-term prognosis reliably and to
select patients who may benefit the most from neoadjuvant
treatment. Lymph node metastasis is one of the most rel-
evant prognostic factors in pancreatic cancer [2]. It is part
of the TNM staging system [3], although its use in selecting
patients for adjuvant treatment and prognostic value has
remained controversial. Studies have shown that lymph
node status can be further refined by calculating the total
number of harvested lymph nodes, providing information
on a minimum of 15 lymph nodes [4], the total number of
positive lymph nodes [5], the lymph node ratio (LNR) [6–
10], extracapsular lymph node involvement [11], direct
invasion of lymph nodes versus true lymph node metastasis
[12], and micrometastatic involvement [13].
Whether to perform an extended lymphadenectomy
during pancreatic resection for adenocarcinoma of the
pancreas is not a new debate. In fact, leading Japanese
surgeons had already adopted extended lymphadenectomy
during the mid-1970s after the concept of regional pan-
createctomy had been introduced by Fortner [14]. These
surgeons justified their new concept of radical lymphade-
nectomy during pancreatic surgery on the basis of other
oncologic resections, such as D3 lymphadenectomy for
gastric cancer [15]. The use of extended lymphadenectomy
for pancreatic cancer, however, failed to gain acceptance in
the Western countries.
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Evidence
Trials
Most studies suggesting an advantage for extended lym-
phadenectomy are nonrandomized retrospective studies
and should therefore be interpreted with caution. A recent
review by Pavlidis et al. [16] summarized the level-A
evidence of four randomized controlled trials on extended
versus standard lymphadenectomy. They arrived at the
conclusion that extended lymphadenectomy does not offer
any benefit in terms of long-term survival.
The first randomized control trial (RCT) was a multi-
center Italian study that randomly assigned 40 patients to
standard pancreatoduodenectomy (PD) and 41 patients to
PD with additional extended lymphadenectomy [17]. As
expected, a significant difference in retrieved lymph nodes
was found between standard and extended PD with,
respectively a mean of 13 versus 20 harvested lymph
nodes. Mortality and morbidity rates between the two
groups were comparable. Of note, on subgroup analysis of
patients with positive lymph nodes only, overall survival
was significantly longer for the group of patients treated by
PD with extended lymphadenectomy.
The largest RCT to date was performed at Johns
Hopkins. They randomly assigned 146 patients to undergo
standard PD and 148 patients to undergo PD with extended
lymphadenectomy, associated with distal gastrectomy in
about one-third of the cases [18, 19]. The Johns Hopkins
trial, however, also included patients with periampullary
carcinoma, distal cholangiocarcinoma, and duodenal car-
cinoma. These entities have different 5-year survivals and
slightly different patterns of lymph node metastasis. The
study found no evidence of extended lymphadenectomy
superiority.
More recently, an RCT from the Mayo Clinic assigned
40 patients to standard PD and 39 patients to PD with
extended lymphadenectomy [20]. Similarly, this study
failed to show a significant difference in overall survival
between patients undergoing PD with standard versus
extended lymphadenectomy. The Mayo Clinic trial also
performed a subgroup analysis on patients with lymph node
metastasis. In contrast to the RCT by Pedrazzoli et al. [17],
no survival difference was found between the two groups.
This difference might be explained by the fact that all
patients in the Mayo Clinic trial underwent adjuvant che-
moradiation following PD.
The most recent multicenter RCT from Japan, by
Nimura et al. [21], randomly assigned 112 patients to either
extended or standard lymphadenectomy during PD for
pancreatic cancer of the head of the pancreas only. Inter-
estingly, in this Japanese trial, none of the patients received
adjuvant chemotherapy—in contrast to a variety of
adjuvant regimens given to patients in the three previously
conducted RCTs. These authors, similarly, failed to iden-
tify a benefit of extended lymphadenectomy in terms of
overall survival. The extent of PD and lymphadenectomy
for both the standard and extended group in the RCTs is
illustrated in Table 1.
All RCTs (except for the Johns Hopkins trial) have been
criticized because of low sample size and hence being
underpowered, leading to a type 2 error. A small difference
in survival difference is also unlikely to be picked up in the
absence of a standardized postoperative treatment. Finally,
the 20 % 2-year overall survival after standard lymphade-
nectomy that was used to calculate the sample size in the
Japanese trial is lower than expected [21]. A major concern
raised by the analysis of the available RCTs along with the
retrospective studies is the increased morbidity associated
with extended lymphadenectomy [22]. In light of similar
overall survival, secondary outcome variables (e.g., severe
complications, operating time, hospital stay, quality of life)
should be given more importance. Indeed, circular dissec-
tion of the celiac trunk and superior mesenteric artery may
cause severe diarrhea because of injury of the periarterial
neural plexus. This type of diarrhea is notably therapy-
resistant and can severely impair the postoperative quality
of life. Also, the extended lymphadenectomy results in a
significant increase in operating time [23]. These draw-
backs may result in significant additional cost (e.g., due to
longer hospitalization times), which are not justified in
view of the absence of any obvious benefit.
Thus, the current evidence does not support performing
extended lymphadenectomy during PD for the treatment of
pancreatic cancer. Interestingly, for adenocarcinoma of the
body and tail of the pancreas requiring distal pancreatec-
tomy (DP) with en bloc splenectomy, the optimal extent of
lymphadenectomy is less clear, as no RCT is available to
support either strategy. Also, in a recent series of 85 patients
with carcinoma of the body and tail of the pancreas, no
correlation was found between the anatomic locations of
metastatic lymph nodes and survival [24]. Their results
suggested that with this type of cancer nodal staging could
be more informative if classified based on the number of
metastatic lymph nodes and the LNR rather than anatomic
location. However, the number of metastatic lymph nodes
and the LNR are influenced by the extent of the resection.
Therefore, although not associated with improved survival,
sufficiently thorough lymph node sampling remains neces-
sary to stage these patients correctly.
Lack of a true standard for lymphadenectomy
during pancreatic cancer surgery
The lack of a true standard for lymphadenectomy during
PD has complicated the interpretation of both retrospective
World J Surg (2013) 37:1782–1788 1783
123
T
a
b
le
1
S
tu
d
y
ch
ar
ac
te
ri
st
ic
s
o
f
th
e
fo
u
r
ra
n
d
o
m
iz
ed
cl
in
ic
al
tr
ia
ls
co
m
p
ar
in
g
st
an
d
ar
d
v
er
su
s
ex
te
n
d
ed
ly
m
p
h
ad
en
ec
to
m
y
d
u
ri
n
g
p
an
cr
ea
ti
co
d
u
o
d
en
ec
to
m
y
P
ed
ra
zz
o
li
[1
7
]
(1
9
9
8
)
Y
eo
[1
8
,
1
9
]
(1
9
9
9
an
d
2
0
0
2
)
F
ar
n
el
l
[2
0
]
(2
0
0
5
)
N
im
u
ra
[2
1
]
(2
0
1
2
)
M
u
lt
i-
ce
n
te
r
S
in
g
le
ce
n
te
r
S
in
g
le
ce
n
te
r
M
u
lt
i-
ce
n
te
r
S
ta
n
d
ar
d
E
x
te
n
d
ed
S
ta
n
d
ar
d
E
x
te
n
d
ed
S
ta
n
d
ar
d
E
x
te
n
d
ed
S
ta
n
d
ar
d
E
x
te
n
d
ed
N
o
.
o
f
p
at
ie
n
ts
4
0
4
1
1
4
6
1
4
8
4
0
3
9
5
1
5
0
R
es
ec
ti
o
n
ty
p
e
P
P
o
r
D
G
P
P
3
0
%
D
G
D
G
P
P
,
S
P
,
D
G
N
o
d
e
d
is
se
ct
io
n
E
n
b
lo
c
S
eq
u
en
ti
al
S
eq
u
en
ti
al
E
n
b
lo
c
L
N
st
at
io
n
s
re
m
o
v
ed
L
N
5
,
6
,
8
,
1
2
,
1
3
,
1
7
L
N
5
,
6
,
7
,
8
,
9
,
1
1
,
1
2
,
1
3
,
1
7
L
N
1
2
a
,
1
3
,
1
4
,
1
7
L
N
3
,
4
,
5
,
6
,
8
,
9
,
1
1
,
1
2
,
1
3
,
1
4
,
1
5
,
1
6
,
1
7
L
N
3
,
4
,
6
,
8
a,
1
2
b
,
1
3
,
1
4
b
,
1
7
L
N
3
,
4
,
6
,
8
(a
,
p
),
1
2
,
1
3
,
1
4
,
1
6
,
1
7
L
N
1
3
,
1
7
L
N
6
,
8
,
9
,
1
2
(a
,
b
,
p
),
1
3
,
1
4
,
1
6
O
p
er
at
in
g
ti
m
e
(m
in
)
3
7
2
3
9
6
3
5
4
3
8
4
3
7
8
4
5
0
4
2
6
5
4
7
N
o
.
o
f
L
N
s
re
m
o
v
ed
1
3
.3
(1
–
3
5
)*
1
9
.8
(3
–
7
6
)*
1
7
*
2
8
.5
*
1
5
(3
–
1
3
)*
3
6
(6
–
7
4
)*
1
3
.3
(4
–
3
0
)*
4
0
.1
(1
5
–
8
1
)*
N
?
st
at
u
s
2
4
(6
0
%
)
2
4
(5
9
%
)
(8
2
%
)
(7
7
%
)
(5
5
%
)
(6
8
%
)
3
2
(6
3
%
)
3
0
(6
0
%
)
R
0
re
se
ct
io
n
2
9
(7
2
.5
%
)
3
2
(7
8
%
)
(8
0
%
)*
(9
5
%
)*
(7
6
%
)
(8
2
%
)
4
8
(9
4
%
)
4
5
(9
0
%
)
A
d
ju
v
an
t
tr
ea
tm
en
t
(n
o
.)
IO
R
T
(1
0
)
IO
R
T
(9
)
C
R
T
(8
1
)
C
R
T
(8
3
)
C
R
T
C
R
T
N
o
n
e
N
o
n
e
M
o
rt
al
it
y
ra
te
2
(5
%
)
2
(5
%
)
6
(4
%
)
3
(2
%
)
0
1
(3
%
)
0
1
(2
%
)
1
-,
3
-,
5
-Y
ea
r
su
rv
iv
al
s
(%
)
–
–
8
0
/4
4
/2
3
(7
5
/3
4
/1
3
%
)
7
7
/4
4
/2
9
(7
3
/3
8
/2
9
%
)
8
2
/4
1
/1
6
7
1
/2
5
/1
7
7
8
/2
8
/1
6
5
4
/1
8
/6
M
ed
ia
n
su
rv
iv
al
(m
o
n
th
s)
1
1
.2
1
6
.7
3
0
.0
2
8
.0
2
6
.0
1
8
.8
1
9
.9
1
3
.8
P
P
p
y
lo
ru
s-
p
re
se
rv
in
g
,
D
G
d
is
ta
l
g
as
tr
ec
to
m
y
,
S
P
su
p
ra
p
y
lo
ri
c
g
as
tr
ic
tr
an
se
ct
io
n
,
L
N
ly
m
p
h
n
o
d
e,
IO
R
T
in
tr
ao
p
er
at
iv
e
ra
d
ia
ti
o
n
th
er
ap
y
,
C
R
T
ch
em
o
ra
d
io
th
er
ap
y
*
S
ig
n
ifi
ca
n
t
d
if
fe
re
n
ce
s
b
et
w
ee
n
th
e
tw
o
g
ro
u
p
s
a
N
o
d
es
in
th
e
lo
w
er
h
ep
at
o
d
u
o
d
en
al
li
g
am
en
t
b
N
o
d
es
in
th
e
ri
g
h
t
h
ep
at
o
d
u
o
d
en
al
li
g
am
en
t
fo
r
L
N
1
2
,
o
n
th
e
su
p
er
io
r
m
es
en
te
ri
c
ar
te
ry
fo
r
L
N
1
4
1784 World J Surg (2013) 37:1782–1788
123
and prospective studies. When looking at the RCTs alone,
all four trials obviously differed regarding the extent of
their standard and extended lymphadenectomies [17, 19–
21]. For instance, although resection of anterior and pos-
terior pancreaticoduodenal lymph nodes (LN17, LN13),
including infrapyloric nodes (LN6) and hepatoduodenal
lymph nodes (LN12), is fairly standardized, resection of
lymph nodes surrounding the common hepatic artery (LN8)
is not. This lack of a true standard makes comparison
among studies problematic. Interestingly, the recently
proposed LNR [i.e., the ratio of involved nodes to the total
number of examined lymph nodes (ELNs)] has been shown
to be an independent prognostic factor after pancreatec-
tomy for pancreatic adenocarcinoma. The LNR strongly
correlates with outcome provided a certain number of
lymph nodes are evaluated, suggesting that the prognostic
accuracy of any lymph node variable depends on the total
number of ELNs [25]. It is likely that the observed relative
benefit of more-extensive lymphadenectomy may lie in a
better prognostic evaluation, rather than any real thera-
peutic effect [26]. Whether more-extensive lymphadenec-
tomy is beneficial to the patient remains unknown when
fewer than a minimum number of lymph nodes (i.e., LN
[15) are harvested [23].
Pattern of recurrence after PD for pancreatic cancer
The pattern of recurrence after PD for pancreatic cancer
has only scarcely been studied. In a recent single-center
study of 145 patients undergoing pancreatic resection for
pancreatic adenocarcinoma, 110 patients developed recur-
rence during follow-up. Locoregional recurrence was
documented in 44 (40 %) of the patients. Of note, isolated
locoregional recurrence was relatively uncommon (17 %),
and liver metastasis was observed in 57 of 110 (52 %)
patients [27]. It is unlikely that extending the degree of
lymphadenectomy would substantially decrease the num-
ber of locoregional recurrences as the majority of them can
be at least partially attributed to R1 resections. Neverthe-
less, among N1 patients, a higher number of positive lymph
nodes and an LNR [0.4 were associated with the highest
rate of local failure following PD and adjuvant 5-fluoro-
uracil-based chemoradiation therapy [28].
Patterns of lymph node metastasis and recurrence
Aside from the lack of evidence to support extended
lymphadenectomy based on the RCTs and prospective
cohort studies, some evidence against extended lymphad-
enectomy may come from the analysis of the distribution
pattern of lymph node metastases of pancreatic cancer.
During the 1970s, Cubilla et al. [29] studied the pattern of
lymph node involvement in cancer of the head of the
pancreas. One-third of 22 extended lymphadenectomies
examined were found to have nodal metastases along the
superior and inferior borders of the corpus of the pancreas.
Until the detailed Japanese landmark studies by Kayahara
et al. [30] and Ishikawa et al. [31], the relative anatomic
distributions of lymph node metastases in pancreatic cancer
were unknown. The lymph node stations most commonly
involved are the posterior pancreaticoduodenal lymph
nodes (51 and 49 %, respectively), the superior mesenteric
artery lymph nodes (37 and 47 %, respectively), and the
inferior pancreaticoduodenal lymph nodes (33 and 37 %,
respectively). The paraaortic lymph nodes were involved in
up to 16 % patients. These data were confirmed in the
Japanese RCT [21]. Of note, these studies showed that
lymph node stations typically falling outside a standard
lymphadenectomy were the sole sites of lymph node
metastases in only 5 % of the cases. The prediction of
distant lymph node metastasis could be helpful not only for
selecting patients for a more extended lymphadenectomy
but also for the use of neoadjuvant therapy. Regarding the
use of extended lymphadenectomy, it is important to
remember that lymph node metastases around the superior
mesenteric artery or any of the other less frequently
involved lymph nodal stations (e.g., splenic artery) are
associated with a poorer prognosis, and such dismal out-
come cannot yet be reversed with a more-extended lym-
phadenectomy. Unlike other tumors such as gastric cancer,
extensive lymph node involvement with pancreatic cancer
should be considered a marker of aggressive tumor biology
and rapid progression. Therefore, lymphadenectomy only
partially contributes to the therapeutic success. Neoadju-
vant therapy may have greater potential when selectively
administered to patients with a high incidence of distant
paraaortic (LN16) lymph node metastasis, which corre-
sponds to those with T3 or higher stage tumors, with
arterial and perineural invasion [32].
It is important to stress that those interaortocaval lymph
nodes (right paraaortic lymph nodes—LN16) for pancreatic
cancer of the head and celiac trunk lymph nodes (LN9) for
tumors of the body and tail of the pancreas are classified as
M1 disease according to the TNM classification [3].
Indeed, paraaortic M1 lymph node spread indicates a poor
prognosis with median survival rates of approximately
6 months. Paraaortic lymph nodes may be involved in up to
30 % of patients undergoing PD, and rejecting those
patients for curative resection would probably result in a
better approach.
Another argument against extended lymphadenectomy
is that pancreatic adenocarcinoma does not exclusively
metastasize via the lymphatic system. Transperitoneal and
subperitoneal spread, including perineural invasion and
periarterial invasion, provide a direct route from the pan-
creas to the peritoneal cavity and retroperitoneum.
World J Surg (2013) 37:1782–1788 1785
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Moreover, hematogenous metastatic routes contribute to
distant spread of the disease. Indeed, both lymphatic and
vascular invasion may lead to the venous circulation of
tumor cells. In addition, it has been suggested that exten-
sive lymph node invasion with extracapsular lymph node
involvement resulting in shunting of tumor cells to the
vascular system drives these alternative routes [11].
In light of the availability of more effective adjuvant
therapies, the potential benefit of extended lymphadenec-
tomy may further shrink. Indeed, about two-thirds of
patients do receive adjuvant therapies after pancreatic
resection for pancreatic adenocarcinoma [33]. On multi-
variable analysis, major postoperative complications were
associated with decreased utilization of adjuvant therapy. If
postoperative morbidity is increased after extended lym-
phadenectomy, more patients will not be fit enough to be
offered chemotherapy and thereby miss their benefits.
Standard lymphadenectomy—Zurich approach
Adenocarcinoma of the head of the pancreas
A standard lymphadenectomy is advisable for almost all
pancreatic adenocarcinomas, as proposed by a recent
expert consensus statement [23]. The extent of lympha-
dectomy is illustrated in Fig. 1 (white lymph node sta-
tions). During PD, interaortocaval lymph nodes (part of
LN16) are sampled during the Kocher maneuver. Positive
interaortocaval lymph nodes are classified as M1 disease
according to the TNM classification, implying a median
survival of no more than 7.8 months for patients with an
extended lymphadenectomy [32]. Therefore, in most cen-
ters, the operation is aborted in older, higher-risk patients if
this lymph node station is seen to be positive on frozen
section. Palliative PD can be considered on a case-by-case
basis. During dissection of the hepatoduodenal ligament,
the lymph nodes surrounding the common hepatic artery
(LN8) and both sides of the hepatoduodenal ligament
(LN12) including the retroportal lymph nodes are dis-
sected—if possible, en bloc with the specimen and distal
bile duct. The infrapyloric (LN6) and suprapyloric (LN5)
lymph nodes are kept with the resection specimen or
sampled in case of partial gastrectomy or harvested if
duodenal preservation is the choice. The gastroepiploic
vein is ligated at its origin from the superior mesenteric or
middle colic veins. The anterior (LN17) and posterior
(LN13) lymph nodes around the superior and inferior
pancreaticoduodenal veins are not dissected from the
specimen and are routinely included with resection of the
head of the pancreas. Particular care is taken to resect
the complete uncinate process and lymph nodes right of the
superior mesenteric artery (LN14). In selected cases with
portal vein involvement, we advocate a superior mesenteric
artery approach, as the first step.
Adenocarcinoma of the corpus or tail of the pancreas
En bloc splenectomy after early ligation of the splenic
artery at its origin of the celiac trunk is performed for distal
pancreatectomy. Radical antegrade modular pancreato-
splenectomy (RAMPS) is an alternative approach when
there is concern about the posterior resection margin [34].
The extent of lymphadenectomy is illustrated in Fig. 1
(black lymph node stations). All the lymph nodes along the
splenic artery (LN11) up to the splenic hilum (LN10) are
resected. Care is taken to remove lymph nodes at the
superior and inferior (LN18) border of the pancreas when
mobilizing the pancreatic tail and body up to the level of
the junction of the splenic and portal vein. Lymph nodes at
the celiac trunk (LN9) and common hepatic artery (LN8)
are also sampled. Complete en bloc clearance of the lymph
nodes around the celiac axis is generally avoided for two
reasons: first to prevent morbidity arising from damage to
the mesenteric nerve plexus; second, because these nodes
are considered M1 in the TNM classification. When posi-
tive those nodes are associated with such a poor prognosis
that resection is no longer justified.
Fig. 1 Standard lymphadenectomy during pancreatectomy for pan-
creatic adenocarcinoma of the head and corpus or tail of the pancreas.
The lymph node stations (according to the Japanese classification
[15]) resected during pancreaticoduodenectomy are white with black
numbers. Lymph node stations resected during en bloc left pancre-
atectomy with splenectomy are black with white numbers. Lymph
nodes around the common hepatic artery (LN8) were resected during
both procedures
1786 World J Surg (2013) 37:1782–1788
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Conclusions
There is currently no evidence for a benefit of extended
lymphadenectomy during surgery for pancreatic adeno-
carcinoma. Other refinements of lymph node staging, such
as the LNR and extra-capsular lymph node invasion may
be stronger predictors of oncologic outcome. However,
based on current scientific evidence, only standard lym-
phadenectomy should be performed routinely during
resection of pancreatic cancer.
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